Patrick A. Baeuerle

Patrick A. Baeuerle's AcademicInfluence.com Rankings

Patrick A. Baeuerle

Biology

#1463

World Rank

#2453

Historical Rank

Immunology

#113

World Rank

#120

Historical Rank

Molecular Biology

#133

World Rank

#137

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Patrick A. Baeuerle Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Patrick Baeuerle is a German-based molecular biologist, immunologist, professor and a biopharmaceutical entrepreneur. Baeuerle is known for his work on tyrosine sulfation of proteins, transcription factor NF-kappaB, and the development of bispecific T-cell engaging antibodies for therapy of cancer.

(See a Problem?)

Patrick A. Baeuerle's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Function and activation of NF-kappa B in the immune system. (1994) (4736)
Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF‐kappa B transcription factor and HIV‐1. (1991) (3835)
NF-κB: Ten Years After (1996) (2938)
I kappa B: a specific inhibitor of the NF-kappa B transcription factor. (1988) (1869)
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells (1992) (1513)
Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). (1992) (1418)
H2O2 and antioxidants have opposite effects on activation of NF‐kappa B and AP‐1 in intact cells: AP‐1 as secondary antioxidant‐responsive factor. (1993) (1325)
Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB (1993) (1031)
Phosphorylation of human I kappa B‐alpha on serines 32 and 36 controls I kappa B‐alpha proteolysis and NF‐kappa B activation in response to diverse stimuli. (1995) (1002)
The inducible transcription activator NF-κB: regulation by distinct protein subunits (1991) (990)
Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor (1988) (982)
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody (2008) (968)
Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B (1990) (905)
NF-kappa B: ten years after. (1996) (903)
Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. (1996) (865)
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. (2011) (839)
The DNA binding subunit of NF-κB is identical to factor KBF1 and homologous to the rel oncogene product (1990) (795)
The p65 subunit is responsible for the strong transcription activating potential of NF‐kappa B. (1991) (793)
Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. (1998) (733)
A proteasome inhibitor prevents activation of NF‐kappa B and stabilizes a newly phosphorylated form of I kappa B‐alpha that is still bound to NF‐kappa B. (1994) (712)
Tyrosine Phosphorylation of IκB-α Activates NF-κB without Proteolytic Degradation of IκB-α (1996) (640)
Nuclear signalling by tumour-associated antigen EpCAM (2009) (640)
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis (1995) (638)
Selective Activation of NF-κB by Nerve Growth Factor Through the Neurotrophin Receptor p75 (1996) (632)
Recent advances torwards understanding redox mechanisms in the activation of nuclear factor κb (2000) (613)
NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. (1997) (578)
Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease (1997) (554)
Bispecific T-cell engaging antibodies for cancer therapy. (2009) (501)
The emerging role of EpCAM in cancer and stem cell signaling. (2009) (497)
A role for oxygen radicals as second messengers. (1991) (492)
The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. (1995) (482)
Nuclear factor kappa B, a mediator of lipopolysaccharide effects. (1993) (481)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. (2012) (443)
The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits. (1993) (443)
Constitutive NF-kappa B activity in neurons (1994) (429)
A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF‐kappa B. (1995) (425)
Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-κB subunit (1992) (407)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. (2012) (403)
Purified human IκB can rapidly dissociate the complex of the NF-κB transcription factor with its cognate DNA (1990) (402)
IκB–NF-κB Structures At the Interface of Inflammation Control (1998) (396)
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. (1991) (388)
Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis (1996) (388)
A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. (1989) (377)
Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. (2000) (368)
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers (2006) (360)
The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB (1996) (352)
Chlorate--a potent inhibitor of protein sulfation in intact cells. (1986) (344)
EpCAM (CD326) finding its role in cancer (2007) (343)
DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. (1991) (329)
Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons. (1995) (328)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. (2016) (325)
IL‐2 gene expression and NF‐kappa B activation through CD28 requires reactive oxygen production by 5‐lipoxygenase. (1995) (322)
The ER-overload response: activation of NF-κB (1997) (321)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct (2005) (313)
Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. (1996) (311)
Regulation of the transcription factors NF-κB and AP-1 by redox changes (1994) (305)
Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. (1999) (301)
Nuclear uptake control of NF‐kappa B by MAD‐3, an I kappa B protein present in the nucleus. (1993) (300)
Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. (1997) (299)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. (2006) (298)
Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody (2002) (296)
Combined transcriptome and genome analysis of single micrometastatic cells (2002) (292)
Pro-inflammatory signaling: Last pieces in the NF-κB puzzle? (1998) (273)
Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. (1993) (272)
Blinatumomab: a historical perspective. (2012) (271)
The primary structure of human secretogranin II, a widespread tyrosine-sulfated secretory granule protein that exhibits low pH- and calcium-induced aggregation. (1989) (271)
IKAP is a scaffold protein of the IκB kinase complex (1998) (267)
NF‐kappa B contacts DNA by a heterodimer of the p50 and p65 subunit. (1991) (262)
Oxygen and the control of gene expression (1994) (259)
IkappaB-NF-kappaB structures: at the interface of inflammation control. (1998) (253)
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. (2006) (251)
Redox signalling by transcription factors NF-κB and AP-1 in lymphocytes (1995) (245)
Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. (1997) (241)
Activation of NF‐κB by ER stress requires both Ca2+ and reactive oxygen intermediates as messengers (1996) (236)
BiTEs: bispecific antibody constructs with unique anti-tumor activity. (2005) (226)
Hydrogen peroxide as a potent activator of T lymphocyte functions (1995) (223)
Tyrosine sulfation is a trans-Golgi-specific protein modification (1987) (220)
Sex reversal by loss of the C–terminal transactivation domain of human SOX9 (1996) (217)
The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. (1991) (215)
Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. (1996) (213)
The primary structure of bovine chromogranin A: a representative of a class of acidic secretory proteins common to a variety of peptidergic cells. (1986) (211)
Hepatitis B virus transactivator MHBst: activation of NF‐kappa B, selective inhibition by antioxidants and integral membrane localization. (1992) (210)
Nuclear import-export: In search of signals and mechanisms (1991) (208)
The primary structure of human secretogranin I (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region. (1987) (207)
Brain synapses contain inducible forms of the transcription factor NF-κB (1993) (206)
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. (2006) (200)
Role of nuclear factor‐kappa B in atherogenesis (1997) (195)
NF-kappa B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene (1990) (194)
EpCAM (CD326) finding its role in cancer (2007) (185)
Expression of the types A and B tumor necrosis factor (TNF) receptors is independently regulated, and both receptors mediate activation of the transcription factor NF-kappa B. TNF alpha is not needed for induction of a biological effect via TNF receptors. (1990) (184)
The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. (1995) (184)
Expression of influenza virus hemagglutinin activates transcription factor NF-kappa B (1995) (181)
Nuclear factor kB is activated by arachidonic acid but not by eicosapentaenoic acid. (1996) (180)
T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct1 (2003) (177)
Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention (1996) (176)
A novel complex between the p65 subunit of NF‐kappa B and c‐Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. (1992) (174)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. (2011) (171)
Transactivation domain 2 (TA2) of p65 NF-kappa B. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. (1995) (170)
Dithiocarbamates as Potent Inhibitors of Nuclear Factor KB Activation in Intact Cells By galf Schreck, Beate Meier,* Daniela N. M~innel,~ Wulf Dr6ge,~ (1992) (169)
A secreted/shed product of Helicobacter pylori activates transcription factor nuclear factor-kappa B. (1997) (168)
Induction of Oxidative Stress by Okadaic Acid Is Required for Activation of Transcription Factor NF-κB (*) (1995) (166)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. (2009) (164)
Interaction of the COOH-terminal Transactivation Domain of p65 NF-κB with TATA-binding Protein, Transcription Factor IIB, and Coactivators (*) (1995) (163)
BiTE: Teaching antibodies to engage T-cells for cancer therapy. (2009) (163)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. (2014) (162)
[14] Assessing oxygen radicals as mediators in activation of inducible eukaryotic transcription factor NF-κB (1994) (159)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen (2010) (152)
Targeting T cells to tumor cells using bispecific antibodies. (2013) (151)
T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells (1996) (148)
Hypoxia Induces c-fos Transcription via a Mitogen-activated Protein Kinase-dependent Pathway* (1997) (146)
KBF1 (p50 NF-kappa B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells (1993) (143)
A revival of bispecific antibodies. (2004) (143)
Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. (1996) (142)
Control of gene expression by proteolysis. (1996) (140)
Structural and functional analysis of the NF-kappa B p65 C terminus. An acidic and modular transactivation domain with the potential to adopt an alpha-helical conformation. (1994) (139)
Transcription factor NF-κB is activated in microglia during experimental autoimmune encephalomyelitis (1994) (139)
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines (2005) (139)
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells (2010) (135)
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct (2003) (131)
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. (2005) (131)
On the abundance of EpCAM on cancer stem cells (2009) (131)
Gene Expression Profiling of Human Stent-Induced Neointima by cDNA Array Analysis of Microscopic Specimens Retrieved by Helix Cutter Atherectomy: Detection of FK506-Binding Protein 12 Upregulation (2001) (130)
Distinct Domains of the RelA NF-κB Subunit Are Required for Negative Cross-talk and Direct Interaction with the Glucocorticoid Receptor* (1997) (130)
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. (2006) (129)
The ER-overload response: activation of NF-kappa B. (1997) (128)
NF-?B as a Frequent Target for Immunosuppressive and (1997) (128)
Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings (1996) (126)
Antioxidants selectively suppress activation of NF-kappa B by human T-cell leukemia virus type I Tax protein (1992) (126)
Dysregulation of Monocytic Nuclear Factor-κB by Oxidized Low-Density Lipoprotein (1997) (125)
The rel-associated pp40 protein prevents DNA binding of Rel and NF-kappa B: relationship with I kappa B beta and regulation by phosphorylation. (1991) (123)
Antioxidant and redox regulation of genes (1999) (122)
The IκB Kinase (IKK) Complex Is Tripartite and Contains IKKγ but Not IKAP as a Regular Component* (2000) (120)
Antioxidants as well as oxidants activate c-fos via Ras-dependent activation of extracellular-signal-regulated kinase 2 and Elk-1. (1997) (120)
Potential involvement of the transcription factor NF-κB in neurological disorders (1993) (120)
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct (2013) (119)
Molecular mechanisms in down-regulation of tumor necrosis factor expression. (1990) (118)
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct (2007) (118)
The 65-kD subunit of NF-kappa B is a receptor for I kappa B and a modulator of DNA-binding specificity. (1990) (117)
Mechanism of the Tumor Necrosis Factor α-mediated Induction of Endothelial Tissue Factor (*) (1995) (116)
EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells (2011) (114)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. (2006) (113)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens (2012) (112)
Reactive oxygen intermediates as second messengers of a general pathogen response. (1996) (110)
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment (2002) (109)
Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia (2014) (106)
IKAP is a scaffold protein of the IkappaB kinase complex. (1998) (105)
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies (2010) (104)
Selective recognition of the activated form of transcription factor NF-kappa B by a monoclonal antibody. (1995) (103)
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. (2007) (102)
Constitutive nuclear NF-kappa B in cells of the monocyte lineage. (1994) (102)
A Subset of Human Dendritic Cells in the T Cell Area of Mucosa-Associated Lymphoid Tissue with a High Potential to Produce TNF-α1 (2003) (99)
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab (2009) (98)
Sphingomyelinase activates proteolytic I kappa B-alpha degradation in a cell-free system. (1994) (97)
Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? (2020) (96)
The proto-oncogene BCL-3 encodes an IκB protein (1992) (95)
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct (2006) (95)
Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class (2007) (94)
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response (2019) (94)
Tyrosine Phosphorylation of IkB-a Activates NF-kB without Proteolytic Degradation of IkB-a (1996) (92)
Transcriptome Analysis Reveals a Role of Interferon-γ in Human Neointima Formation (2001) (87)
Differential activation of transcription factors NF‐ϰB and AP‐1 in rat liver macrophages (1995) (86)
Phorbol-ester-induced activation of the NF-kappa B transcription factor involves dissociation of an apparently cytoplasmic NF-kappa B/inhibitor complex. (1988) (86)
The NF-ϰB transcription factor induces DNA bending which is modulated by its 65-kD subunit (1990) (83)
Proteins controlling the nuclear uptake of NF-κB, Rel and dorsal (1991) (83)
Tyrosine sulfation of yolk proteins 1, 2, and 3 in Drosophila melanogaster. (1985) (82)
Brain synapses contain inducible forms of the transcription factor NF-kappa B. (1993) (80)
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. (2007) (80)
Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells (2010) (79)
Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA (2009) (78)
Purified I kappa B-beta is inactivated upon dephosphorylation. (1992) (78)
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. (2008) (78)
Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappaB. (1996) (77)
Regulation of the transcription factors NF-kappa B and AP-1 by redox changes. (1994) (76)
Protein sulfation on tyrosine (1988) (75)
Multi-Step Activation of NF-κB/Rel Transcription Factors (1995) (74)
Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? (1998) (73)
Assessing oxygen radicals as mediators in activation of inducible eukaryotic transcription factor NF-kappa B. (1994) (71)
Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes. (1995) (71)
Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. (2009) (70)
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas (2014) (70)
Phenotype and function of human dendritic cells derived from M‐DC8+ monocytes (2001) (69)
Purified human I kappa B can rapidly dissociate the complex of the NF-kappa B transcription factor with its cognate DNA. (1990) (66)
Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy (2005) (65)
Interleukin‐1β Uses Common and Distinct Signaling Pathways for Induction of the Interleukin‐6 and Tumor Necrosis Factor α Genes in the Human Astrocytoma Cell Line U373 (1996) (65)
Purification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcription (1994) (64)
The physiology of the NF-κB transcription factor (1991) (62)
Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor α-independent mouse model (2008) (62)
Human T cell leukemia virus-I (HTLV-I) Tax-mediated apoptosis in activated T cells requires an enhanced intracellular prooxidant state. (1998) (61)
Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release (2009) (60)
The dual effect of adenovirus type 5 E1A 13S protein on NF-kappaB activation is antagonized by E1B 19K (1996) (60)
NF-kappa B activation in human knee-joint synovial tissue during the early stage of joint inflammation. (1997) (60)
Nuclear factor kappa B activates proenkephalin transcription in T lymphocytes (1991) (59)
Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing (2017) (58)
Endoplasmicreticulum-induced signal transduction and gene expression. (1997) (57)
Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NF-kappa B. (1993) (55)
Novel antineoplastic agents with efficacy against multidrug resistant tumor cells. (1998) (55)
Regulation ofTumorNecrosis Factor AlphaTranscription in Macrophages: Involvement ofFourKB-Like Motifs andof Constitutive andInducible FormsofNF-KB (1990) (55)
Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. (2004) (55)
Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. (2001) (54)
Tumor necrosis factor β (TNF-β) induces binding of the NF-κB transcription factor to a high-affinity κB element in the TNF-β promoter (1990) (53)
Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors (2017) (52)
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3 (2006) (51)
Bispecific antibodies for polyclonal T-cell engagement. (2003) (51)
GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice (2006) (51)
Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes. (1996) (50)
Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty (2005) (50)
Appearance of apparently ubiquitin-conjugated IκB-α during its phosphorylation-induced degradation in intact cells (1995) (50)
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL (2017) (49)
Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. (2007) (49)
A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. (2006) (48)
Basal transcription factors TBP and TFIIB and the viral coactivator E1A 13S bind with distinct affinities and kinetics to the transactivation domain of NF-kappaB p65. (1997) (46)
Potential involvement of the transcription factor NF-kappa B in neurological disorders. (1993) (45)
The role of the p50 and p65 subunits of NF-kappa B in the recognition of cognate sequences. (1991) (42)
Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four KB-Like Motifs and of Constitutive and Inducible Forms of NF-KB (2003) (41)
Redox Control of Gene Expression by Eukaryotic Transcription Factors NF-κB, AP-1 and SRF/TCF (1994) (41)
Inhibition of N‐glycosylation induces tyrosine sulphation of hybridoma immunoglobulin G. (1984) (40)
The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture (2013) (40)
Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells (2011) (38)
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans (2008) (38)
The proto-oncogene bcl-3 encodes an I kappa B protein. (1992) (37)
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. (2012) (35)
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. (2007) (34)
KBF 1 ( p 50 NF-gB Homodimer ) . Acts as a Repressor of H-2 K b Gene Expression in Metastatic Tumor Cells (1993) (33)
Tumor necrosis factor beta (TNF-beta) induces binding of the NF-kappa B transcription factor to a high-affinity kappa B element in the TNF-beta promoter. (1990) (31)
Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach. (2006) (31)
Efficient tumor cell lysis by autologous, tumor‐resident T lymphocytes in primary ovarian cancer samples by an EP‐CAM‐/CD3‐bispecific antibody (2003) (31)
Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy (2010) (31)
Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110 (2011) (31)
Reactive Oxygen Intermediates as Primary Signals and Second Messengers in the Activation of Transcription Factors (1997) (30)
A 65-kD subunit of active NF-KB is required for inhibition of NF-KB by IKB (2007) (29)
BiTE: a new class of antibodies that recruit T-cells (2008) (29)
The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA (2012) (29)
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. (2006) (28)
Activation of NF-kB by nerve growth factor through the neurotrophin receptor p75 (1996) (28)
Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. (2003) (26)
Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs (2018) (26)
Selection of a muramyl peptide based on its lack of activation of nuclear factor‐κB as a potential adjuvant for AIDS vaccines (1992) (25)
Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study. (2008) (25)
Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. (2006) (24)
Purification of yolk protein 2 of Drosophila melanogaster and identification of its site of tyrosine sulfation. (1988) (24)
Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells (2003) (24)
Abstract #3252: Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110 (2009) (23)
Structural analysis, expression, and chromosomal localization of the mouse ikba gene (1999) (22)
trans-Activation of the HIV type 1 promoter by 7,8-dihydroneopterin in vitro. (1997) (22)
Multi-step activation of NF-kappa B/Rel transcription factors. (1995) (22)
Interleukin-1 beta uses common and distinct signaling pathways for induction of the interleukin-6 and tumor necrosis factor alpha genes in the human astrocytoma cell line U373. (1996) (21)
The role of NF-kappa B1 (p50/p105) gene expression in activation of human blood T-lymphocytes via CD2 and CD28 adhesion molecules. (1993) (21)
The NF-kappa B transcription factor induces DNA bending which is modulated by its 65-kD subunit. (1990) (20)
Targeting of humanized antibody D93 to sites of angiogenesis and tumor growth by binding to multiple epitopes on denatured collagens. (2007) (19)
Antitumor Activity of a Dual Cytokine/Single-chain Antibody Fusion Protein for Simultaneous Delivery of GM-CSF and IL-2 to Ep-CAM Expressing Tumor Cells (2006) (19)
Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL). (2009) (18)
Highly efficient antigen targeting to M-DC8+ dendritic cells via FcgammaRIII/CD16-specific antibody conjugates. (2005) (18)
Activation of the transcription factor NF-kB in inflamed synovial tissue (1996) (17)
Differential activation of transcription factors NF-kappa B and AP-1 in rat liver macrophages. (1995) (17)
Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma (2018) (17)
Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110 (2015) (17)
Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110 (2009) (17)
Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa B. (1991) (16)
Expression, tyrosine sulfation, and secretion of yolk protein 2 of Drosophila melanogaster in mouse fibroblasts. (1988) (15)
Failure of the splicing variant p65 delta of the NF-kappa B subunit p65 to transform fibroblasts. (1994) (15)
Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection (2017) (15)
MYELOID NEOPLASIA CD 33 target validation and sustained depletion of AML blasts in long-term cultures by the bispeci fi c T-cell – engaging antibody AMG 330 (2013) (14)
A Hydrophobic Region within the Adenovirus E1B 19 kDa Protein Is Necessary for the Transient Inhibition of NF-κB Activated by Different Stimuli* (1996) (13)
Productivity and Quality of Recombinant Proteins Produced by Stable CHO Cell Clones can be Predicted by Transient Expression in HEK Cells (2013) (13)
TriTACs, a Novel Class of T-Cell–Engaging Protein Constructs Designed for the Treatment of Solid Tumors (2020) (13)
Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model (2007) (13)
A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells. (2006) (12)
Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m2/d of BiTE® Antibody Blinatumomab. (2009) (12)
Correction: Isolation of a rel-Related Human cDNA That Potentially Encodes the 65-kD Subunit of NF-kappaB (1991) (12)
The histidine tail of recombinant DNA binding proteins may influence the quality of interaction with DNA. (1996) (12)
Transcription factor NF-kB/Rel is activated in the atherosclerotic lesion. (1996) (12)
Appearance of apparently ubiquitin-conjugated I kappa B-alpha during its phosphorylation-induced degradation in intact cells. (1995) (12)
Enter a polypeptide messenger (1995) (12)
Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells (2009) (11)
The 65-kD subunit of NF-KB is a receptor for IKB and a modulator of DNA-binding specificity (2007) (11)
Characterization of a new tissue-specific transcription factor binding to the simian virus 40 enhancer TC-II (NF-kappa B) element (1992) (10)
Transactivation Domain 2 (TA2) of p65 NF-κB (1995) (10)
final Results From A Phase 1 Study Of Blinatumomab In Patients With Relapsed/refractory Non-hodgkin's Lymphoma : 302 (2013) (9)
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL (2022) (9)
Implications of T cell receptor biology on the development of new T cell therapies for cancer. (2020) (9)
Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer. (2012) (8)
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. (2012) (8)
The Rel-associated pp40 protein prevents DNA binding of Rel and NF-KB: relationship .with IKBI3 and regulation by phosphorylatlon (2007) (8)
Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors (2020) (8)
Transcription factor NF-kB is activated in primary neurons by amyloid b peptides and in neurons surrounding early plaques from patients with Alzheimer disease (reactive oxygen intermediatesysenile plaquesyneuroprotectionyH2O2yneuronal cell death) (1997) (7)
A new interference footprinting method for analysing simultaneously protein contacts to phosphate and guanine residues on DNA. (1995) (7)
Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL (2008) (7)
A vector, pHisGal, allowing bacterial production of proteins fused to a hexahistidine-tagged Gal4 DNA-binding domain. (1994) (7)
Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. (2007) (7)
Therapeutic Window of MuS 110 , a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD 3 (2007) (6)
Cloning of the murine relA (p65 NF-kappa B) gene and comparison to the human gene reveals a distinct first intron. (1996) (6)
Proteins controlling the nuclear uptake of NF-kappa B, Rel and dorsal. (1991) (6)
Abstract 1773: HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer (2018) (6)
Abstract 1781: HPN536, a T cell-engaging, mesothelin/CD3-specific TriTAC for the treatment of solid tumors (2018) (6)
Nuclear Factor KB Activates Proenkephalin Transcription in T Lymphocytes (6)
Regulation of Gene Expression by Oxidative Stress (1998) (5)
Transcriptional activators. Enter a polypeptide messenger. (1995) (5)
Abstract 4841: Lysis of cancer cells by highly purified T regulatory cells engaged via an EpCAM/CD3-bispecific BiTE antibody (2012) (5)
Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction (2008) (5)
PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells (2014) (5)
Activation of human immunodeficiency virus long terminal repeat by arachidonic acid. (1997) (5)
Bispecific T Cell Engager for Cancer Therapy (2011) (4)
Abstract 3526: Subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice (2012) (4)
Developmental and tissue-specific expression of the Q5k gene (1991) (4)
8 - Reactive Oxygen Species as Costimulatory Signals of Cytokine-Induced NF- k B Activation Pathways (2000) (4)
The Bi-Specific T-Cell Enhancer (BiTE) MT103 (MEDI-538) Induces Clinical Responses in Heavily Pre-Treated NHL Patients: Update from the Ongoing Phase I Study MT103-104. (2006) (4)
Constitutive nuclear NF-KB in cells of the monocyte lineage (2005) (4)
Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples (2013) (4)
The Transcription Factor TCF/Elk-1 (1996) (3)
Abstract 1790: Functional importance of EpCAM for the activity of tumor-initiating cancer cells and their eradication by EpCAM/CD3-bispecific antibody MT110 (2011) (3)
Abstract 2307: Preclinical evaluation of TC-210, a mesothelin-specific T cell receptor (TCR) fusion construct (TRuC™) T cells for the treatment of solid tumors (2019) (3)
Micromet: engaging immune cells for life (2002) (3)
A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex. (2007) (3)
Abstract 2584: The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope present in the full-length but not a short splice variant of CEA (2010) (3)
Therapeutic window of MuS110, a single-chain antibody construct bispecific for EpCAM (CD326) and CD3 (2007) (3)
Chapter 23 - Kinases in Pro-Inflammatory Signal Transduction Pathways: New Opportunities for Drug Discovery (1998) (3)
The promise of bispecific antibodies. (2004) (3)
Functional analysis of mutated cDNA clones by direct use of PCR products in in vitro transcription/translation reactions. (1993) (3)
The transcription factor TCF/Elk-1: a nuclear sensor of changes in the cellular redox status. (1996) (3)
Resurgence of Bispecific Antibodies (2013) (3)
Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab. (2009) (3)
Conversion of Cetuximab and Trastuzumab into T cell-engaging BiTE antibodies creates novel drug candidates with superior anti-tumor activity (2008) (3)
Human therapies as a successful liaison between chemistry and biology. (2014) (2)
Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models (2008) (2)
Abstract 2433: Eradication of established pancreatic tumors in mice by engagement of extra-tumoral human T cells with BiTE antibody MT110 (2010) (2)
Environmental stresses and nutrients (1995) (2)
Abstract 3589: Preclinical evaluation of mesothelin-specific T cell receptor (TCR) fusion constructs (TRuC™s) utilizing the signaling power of the complete TCR complex: A new opportunity for solid tumor therapy (2018) (2)
Activation of NF-kappa B precursor. (1989) (2)
Development of T‐Cell‐Engaging Bispecific Antibody Blinatumomab (Blincyto®) for Treatment of B‐Cell Malignancies (2018) (2)
The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. (2011) (2)
Inducible Gene Expression, Volume 1 (1995) (2)
Abstract 3814: TriTACs are novel T cell-engaging therapeutic proteins optimized for the treatment of solid tumors and for long serum half-life (2018) (2)
study of blinatumomab in patients with MRD in B-lineage ALL Long-term follow-up of hematologic relapse-free survival in a phase 2 (2012) (2)
Characterization of novel CD33- and MCSP-specific BiTE antibodies for the treatment of acute myeloid leukemia and melanoma, respectively, that are fully human in sequence (2008) (2)
Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells (2014) (2)
Bacterial expression, purification, and potential use of His-tagged GAL4 fusion proteins. (1997) (2)
A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. (2004) (2)
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities (2022) (1)
Transcription factor NF-kB is activated in primary neurons by amyloid ß peptide and in neurons surrounding early plaques from AlzheimerŽs disease patients. (1997) (1)
Abstract 2435: Validation of Cynomolgus monkeys as relevant species for safety assessment of a novel human BiTE antibody platform for cancer therapy (2010) (1)
IL-1b uses common and distinct signalling pathways for induction of the IL-6 and TNF-a genes in the astrocytoma cell line U373. (1996) (1)
Mode of action of MT110, a novel bispecific single-chain antibody construct of the BiTE class for treatment of adeno and squamous cell carcinoma expressing EpCAM (CD326) (2007) (1)
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response (2019) (1)
Phase I study of the novel fully human monoclonal antibody MT201, directed against epithelial cellular adhesion molecule (Ep-CAM), in patients with hormone-refractory prostate cancer (HRPC). (2004) (1)
Abstract 5626: Single-chain bispecific BiTE antibody specific for CD3 and melanoma-associated chondroitin sulfate proteoglycan: In vitro and in vivo anti-melanoma activity (2010) (1)
Abstract 2078: CLN-049 is a bispecific T cell engaging IgG-like antibody targeting FLT3 on AML cells (2022) (1)
BiTE Antibodies for Cancer Therapy (2013) (1)
Abstract #3248: Anti-tumor activity of a T cell-engaging MCSP-specific BiTE antibody at very low effector to target ratios: A new approach to treat metastatic melanoma (2009) (1)
Inhibition ofN-glycosylation induces tyrosine sulphation ofhybridoma immunoglobulin G (1984) (1)
Rationale for Treatment of Colorectal Cancer with EpCAM Targeting Therapeutics (2009) (1)
Abstract 4622: A novel CD33/CD3-bispecific BiTE antibody can effectively recruit autologous T cells from AML-patients for in vitro cell lysis of CD33+ blasts (2012) (1)
Abstract 4561: Preclinical characterization of MT112/BAY 2010112, a novel PSMA/CD3-bispecific BiTE antibody for the treatment of prostate cancer (2011) (1)
Inducible Gene Expression, Volume 2 (1995) (1)
Signal Transduction from the Cytoplasm to the Cell Nucleus by NF-κB/Rel Transcription Factors (1995) (1)
Abstract 2434: Novel primate-crossreactive BiTE antibodies that eliminate cancer cells expressing cMet, IGFR-1, FAP-alpha, PSCA, Endosialin, CAIX or Her2/neu (2010) (1)
Speci ® c depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo (1)
Nuclear signaling by tumor- and stem cell-associated antigen CD326 (EpCAM) (2007) (1)
Abstract 5625:In vitroandin vivopharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas (2010) (1)
Autologous T Cells From AML Patients Can Be Effectively Recruited for In-Vitro Lysis of Blasts by a Novel CD33/CD3-Bispecific BiTE Antibody (2010) (1)
Construct Bispecific for Murine EpCAM and Murine CD 3 Therapeutic Window of MuS 110 , a Single-Chain Antibody (2007) (0)
Highly efficient elimination of melanoma cells expressing melanoma-associated chondroitin sulfate proteoglycan (MCSP) by MCSP/CD3-bispecific single-chain antibody constructs (2007) (0)
Abstract 5340: Impact of binding epitope and antigen size on the cytotoxic activity of MCSP-specific BiTE antibodies for treatment of melanoma (2010) (0)
Correction (1991) (0)
Abstract 3505: CLN-617 is an IL-2/IL-12 fusion protein with a collagen-anchoring domain that induces potent systemic anti-tumor immunity upon intra-tumoral administration (2022) (0)
Polypeptides containing compositions (2004) (0)
Potent tumor killing and inhibition of tumor growth by CEA/CD3-bispecific single chain antibodies that are resistant to inhibition by soluble CEA (2007) (0)
Correct TandAb protein (2007) (0)
[15]Identification of transcription factors and their target genes (1996) (0)
Strong Activator of Transcription (0)
Cancer Therapy : Preclinical EpCAM / CD 3-Bispeci fi c T-cell Engaging Antibody MT 110 Eliminates Primary Human Pancreatic Cancer Stem Cells (2012) (0)
Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors (2023) (0)
Characterization of a New Tissue-Specific Factor Binding to the Simian Virus 40 TC-II (NF-FB) Element Transcription Enhancer (0)
Highly efficient T cell stimulation by targeting of HCV-epitope antibody conjugates to antigen-presenting cells (2001) (0)
of NF-kappaB by I kappaB. A 65-kappaD subunit of active NF-kappaB is required for inhibition (2011) (0)
Abstract 2077: Preclinical characterization of a next-generation CD19/CD3-bispecific T cell engager with extended serum half-life and superior potency against CD19-low target cells (2022) (0)
Engaging Antibody − Tumor Regression in Cancer Patients by Very Low Doses of a T Cell (2012) (0)
Compositions and methods for t-cell receptors reprogramming using fusion proteins (2017) (0)
Antibody Construct CD 19-/ CD 3-Bispecific Single-Chain Human B Cell Lymphoma Xenografts by a Mice Bearing Subcutaneous or Leukemic Efficacious Inhibition of Tumor Growth in T Cell Costimulus-Independent and Very (2003) (0)
Abstract 3524: A novel approach to targeting mutated colorectal adenocarcinomas with T cell-engaging CEA/CD3-bispecific BiTE investigational antibody MEDI-565 (2012) (0)
Rapid characterization of lambda cDNA clones after amplification and radioactive labeling with the PCR technique. (1993) (0)
Epithelial cellular adhesion molecule (Ep-CAM) upregulation in chronic necroinflammatory liver diseases and hepatocellular carcinoma (2004) (0)
Means and methods for the treatment of tumor diseases (2006) (0)
Abstract 2330: Preclinical evaluation of TC-110: CD19-specific T cell receptor (TCR) fusion construct (TRuC™) T cell for the treatment of hematologic malignancies (2019) (0)
224 POSTER Characterization of a murine EpCAM/CD3-bispecific BiTE molecule as a surrogate for preclinical development of the human EpCAM/CD3-bispecific BiTE molecule MT110 (2006) (0)
Bispecific T cell-recruiting antibody constructs for cancer therapy : Therapie mit monoklonalen Antikörpern: aktueller Stand und Perspektiven (2005) (0)
DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody (2010) (0)
Inducible Gene Expression, Volume 1: Environmental Stresses and Nutrients (2012) (0)
Activation of T Cells by Bispecific Single-Chain Construct MT103 (MEDI-538) Is Strictly Target Cell-Dependent. (2006) (0)
Contents Vol. 85, 2010 (2010) (0)
Subject Index Vol. 85, 2010 (2010) (0)
Immunotherapy using bispecific T cell engager (BiTE®) antibodies: preclinical and clinical experience in acute leukemia (2014) (0)
Antibody therapy (SY5-2) Chairpersons: Norihiro Nishimoto, Jeffrey V. Ravetch (2010) (0)
876 Intratumoral administration and local retention of IL-2/IL-12 fusion proteins drive a potent systemic anti-tumor immune response (2021) (0)
Human T Cell Leukemia Virus-I ( HTLV-I ) Tax-Mediated Apoptosis in Activated T Cells Requires an Enhanced Intracellular Prooxidant State 1 (1998) (0)
Abstract 3584: Characterization of a novel class of engineered (TCR) fusion constructs (TRuCTMs) aimed to treat solid tumors (2018) (0)
Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients. (2009) (0)
Targeting Pleural Carcinoma Cells with the Anti-EpCAM BiTE Antibody MT110 by Stimulating Microenvironment T Cells. (2009) (0)
Abstract LB-232: BiTE antibody constructs can mediate bystander tumor cell killing (2015) (0)
Tissue with a High Potential to Produce TNF-Cell Area of Mucosa-Associated Lymphoid A Subset of Human Dendritic Cells in the T (2003) (0)
Modulation of HIV-1 Long Terminal Repeat by Arachidonic Acid (1997) (0)
Straight Mini Antibodies (1999) (0)
Method of inhibiting gene transcription. (1994) (0)
Abstract 3523: Preclinical characterization of MT114, a novel CD33/CD3-bispecific BiTE antibody for the treatment of acute myeloid leukemia (AML) (2012) (0)
Abstract 2429: Evidence of a therapeutic window with a T cell-engaging BiTE antibody based on monoclonal antibody cetuximab (2010) (0)
Abstract 2076: Opal is a conditional 4-1BB agonistic fusion protein comprising trimerized 4-1BB ligand and a high affinity variant of the extracellular domain of PD-1 (2022) (0)
Abstract 4734: Impact of various immune escape mechanisms on redirected lysis by T cells engaged via EpCAM/CD3 bispecific BiTE® antibody AMG 110 . (2013) (0)
Inducible Gene Expression, Volume 2: Hormonal Signals (2012) (0)
Cancer Therapy: Preclinical EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells (2012) (0)
Abstract 5339: Inhibition of breast cancer cell proliferation and unique epitope recognition by EpCAM-specific human monoclonal antibody adecatumumab (2010) (0)
Highly reduced incidence of new breast cancer metastases during treatment with adecatumumab appears to be the major factor for longer time to tumor progression in patients with high-level EpCAM expression (2007) (0)
Abstract 5621: MCSP/CD3-bispecific single-chain antibody construct engages CD4+ and CD8+ T cells for lysis of MCSP-expressing human uveal melanoma cells (2010) (0)
Requires an Enhanced Intracellular Tax-Mediated Apoptosis in Activated T Cells Human T Cell Leukemia Virus-I (HTLV-I) (2013) (0)
Constructions (poly)peptidiques desimmunisees (2003) (0)
Passive immunotherapy by T cell–engaging bispecific antibodies (2011) (0)

This paper list is powered by the following services:

Other Resources About Patrick A. Baeuerle

en.wikipedia.org

What Schools Are Affiliated With Patrick A. Baeuerle?

Patrick A. Baeuerle is affiliated with the following schools:

Patrick A. Baeuerle's Academic­Influence.com Rankings

Why Is Patrick A. Baeuerle Influential?

Patrick A. Baeuerle's Published Works

Published Works

Other Resources About Patrick A. Baeuerle

What Schools Are Affiliated With Patrick A. Baeuerle?

Patrick A. Baeuerle's AcademicInfluence.com Rankings